SCHEMBL2834971

SCHEMBL2834971

COc1cc(C)c(S(=O)(=O)N2CCC[C@H]2COc2nccc(N3CCN(C)CC3)n2)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 2/20 0.38
TMEM97 Q5BJF2 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
CASP3 P42574 11/20 0.38
CASP7 P55210 8/20 0.38
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HRH4 Q9H3N8 1/20 0.36
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
HSD17B10 Q99714 1/20 0.35
USP2 O75604 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
CASP9 P55211 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2835902 0.97 ALDH1A1 (0.38) HTR7TMEM97SIGMAR1CASP3CASP7
SCHEMBL2361261 0.94 BDKRB1 (0.40) HTR7TMEM97SIGMAR1CASP3CASP7
SCHEMBL2834743 0.94 BDKRB1 (0.40) HTR7TMEM97SIGMAR1CASP3CASP7
SCHEMBL2830988 0.92 KMT2A (0.40) HTR7TMEM97SIGMAR1CASP3CASP7
SCHEMBL2833988 0.91 BDKRB1 (0.39) CASP3CASP7ALDH1A1KDM4ELMNA
SCHEMBL2832620 0.91 BDKRB1 (0.39) CASP3CASP7ALDH1A1KDM4ELMNA
SCHEMBL2360744 0.91 CASP3 (0.41) HTR7TMEM97SIGMAR1CASP3CASP7
SCHEMBL2835399 0.91 HTR2A (0.41) HTR7TMEM97SIGMAR1CASP3CASP7
SCHEMBL2835479 0.89 KDM4E (0.41) CASP3CASP7ALDH1A1KDM4ELMNA
SCHEMBL2836723 0.89 HTR7 (0.42) HTR7TMEM97SIGMAR1CASP3CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US claimed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS HTR7 643/4885TMEM97 3649/4885SIGMAR1 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.